Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03035422
Other study ID # 2016-A00862-49
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 15, 2018
Est. completion date December 18, 2021

Study information

Verified date July 2022
Source Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available.


Description:

The goal is to evaluate the efficacy and safety of the combination of an SET followed by haploidentical transplant with post-transplant immune modulation by prophylactic DLI in patients with refractory acute myeloid leukemia or relapsed. The main objective is to assess overall survival at 2 years in these patients. Secondary objectives: 1. To evaluate the efficacy of this therapeutic strategy in terms of remission of disease, incidence of relapse and relapse-free survival 2. To evaluate the non-relapse mortality 3. To evaluate the incidence of acute and chronic graft against host disease (GVHD) 4. To assess the feasibility of prophylactic injections of donor lymphocytes (pDLI) 5. To analyze the post-transplant immune reconstitution Secondary endpoints: 1. partial or complete remission rate by standard criteria at 90 days and then 6, 12 and 24 months after transplantation. Relapse incidence and death related to the disease 90 days 6, 12 and 24 months after transplantation Leukemia-free survival at 1 year and 2 years after transplantation 2. Cumulative incidence of death not related to relapse at 90 days, 1 year and 2 years after transplantation 3. Cumulative incidence of acute and chronic graft against host disease (GVHD) 4. Number of patients for whom pDLI was possible and number of pDLI / patient; incidence, severity and treatment of possible secondary GVHD in these patients 5. Study of immune reconstitution post-transplant in the peripheral blood 30, 90 and 180 days after transplantation (CD4 lymphocyte levels, CD8, T regulators, Natural Killer cells and B cells) Methodology, experimental design: Multicenter study in routine care, prospective All patients will receive, as part of the marketing authorization of the products used, the following regimen: 1- sequential Packaging (SET): 1. sequential chemotherapy: - Thiotepa 5 mg / kg / day for 1 day (D-13) - Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9) - Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) 2. Rest days J-8 and J-6 3. Reduced-intensity conditioning (RIC) - Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1) - Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4) - Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2) 2 Graft transfusion: the day D0. A graft of peripheral stem cells is preferred. 3- Prevention of GVHD: - Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6) - Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6) 4- Care supports: according to the protocols of each center 5- lymphocyte injection of prophylactic donor (pDLI): according to the protocols of each center. The following scheme is proposed: - In the absence of clinical contraindication(GVHD), tapering MMF between days D + 35 and D + 56, then tapering CSA between D + 62 and D + 90 - pDLI: 3 injections from the D + 120 in patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II. 6. Feedback: at baseline and 1, 3, 6, 12 and 24 months after transplant (engraftment, disease response, immune reconstitution, chimerism, GVHD, infection, quality of life). The treatments evaluated in this strategy are all used in the usual care of patients and follow-up will not be changed.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 18, 2021
Est. primary completion date December 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients with a confirmed diagnosis of acute myeloid leukemia after primary induction treatment failure (persistent leukemia after 2 cycles of induction chemotherapy) - Patient age = 18 to <60 years - Cardiac ejection fraction of the left ventricle = 45% - Lung function - free diffusion capacity for carbon monoxide = 50% of predicted value - Creatinine clearance = 50 ml / min depending on the CKD-EPI formula - Availability of an HLA haploidentical donor in the family - Collection of non-opposition Exclusion Criteria: - Uncontrolled invasion of CNS - Availability of an HLA identical family donor who agreed to donate hematopoietic stem cells OR non-related donor HLA-compatible 10/10 on HLA-A alleles, B, C, and DRB1 DQB1 available and ready to give in 4 weeks to make a decision allograft - Presence in the patient HLA-specific antibodies directed against an antigen HLA haploidentical donor family - Karnofsky score <70% - Patient HIV positive - Hepatitis B or C or chronic active - Uncontrolled infection at the time of start packing - Contraindication to the use of treatments provided by the Protocol - Previous history of allo-HSC - No beneficiary of a social security scheme.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sequential Packaging (SET)
Sequential chemotherapy: Thiotepa 5 mg / kg / day for 1 day (D-13) Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9) Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC) Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1) Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4) Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
Transfusion graft
Graft of peripheral stem cells is preferred at D0
Prevention of GVHD
Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5 Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6) Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)
Care supports
According to the protocols of each center
Lymphocyte injection of prophylactic donor (PDLI)
According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90 - PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for = 1 month and having no active GVHD or history of acute GVHD grade> II

Locations

Country Name City State
France Service d'hématologie Clinique Hôpital Saint Antoine Paris

Sponsors (1)

Lead Sponsor Collaborator
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) The aim is to describe the efficacy of the combination of a SET followed by haploidentical transplant with post-transplant immune modulation by pDLI in patients with AML.
The main objective is to assess overall survival at 2 years in these patients.
2 years after transplantation
Secondary Partial or complete remission rate by standard criteria Relapse incidence and death related to the disease To evaluate the efficacy of this therapeutic strategy in terms of remission of disease, incidence of relapse 90 days and then 6, 12 and 24 months after transplantation
Secondary Cumulative incidence of death not related to relapse Assess not related to relapse mortality 90 days and then 12 and 24 months after transplantation
Secondary Cumulative incidence of acute and chronic graft against host disease (GVHD) To evaluate the incidence of acute and chronic graft against host disease (GVHD) 100 days and then 12 and 24 months after transplantation
Secondary Number of patients for whom pDLI was possible. Assess the feasibility of prophylactic injections of donor lymphocytes (pDLI) 2 years after transplantation
Secondary Study of immune reconstitution post-transplant in the peripheral blood will be used:CD4 lymphocyte levels, CD8, T regulators, Natural Killer cells and B cells Study the post-transplant immune reconstitution 90 days and then 6, 12 and 24 months after transplantation
Secondary Leukemia free survival Relapse-free survival 90 days and then 6, 12 and 24 months after transplantation
Secondary Number of pDLI / patient; incidence, severity and treatment of possible secondary GVHD in these patients Assess the feasibility of prophylactic injections of donor lymphocytes (pDLI) 90 days and then 6, 12 and 24 months after transplantation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02890329 - Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT04975919 - Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Terminated NCT02882321 - Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT03214562 - Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Completed NCT02509546 - 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT03683433 - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Phase 2
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Completed NCT02070458 - Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT03557970 - JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Recruiting NCT03661307 - Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03629171 - Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Phase 2
Recruiting NCT05396859 - Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Phase 1
Terminated NCT03067571 - Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 2
Completed NCT04146038 - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Phase 2
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Active, not recruiting NCT04207190 - Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04047641 - Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Withdrawn NCT04493099 - Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML Phase 1/Phase 2